Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Hoffmann, Christopher J ^a   Chaisson, Richard E ^a   Martinson, Neil A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Perinatal HIV Research Unit   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; SOUTH AFRICA; SPUTUM CULTURE; SPUTUM SMEAR; STAGING; TUBERCULOSIS; WHO CLINICAL STAGE;

ADULT; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; SOUTH AFRICA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUBERCULOSIS;

EID: 84896981687     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083750     Document Type: Article

References (19)

1. Ansari NA, Kombe AH, Kenyon TA, Hone NM, Tappero JW, et al. (2002) Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. IntJ TubercLung Dis 6: 55-63. (Pubitemid 34263546)
2. Martinson NA, Hoffmann CJ, Chaisson RE (2011) Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. ProcAm ThoracSoc 8: 288-293.
3. World Health Organization (2012) Global tuberculosis report 2012. Geneva, Switzerland. WHO/HTM/TB/2012.6 WHO/HTM/TB/2012.6.
4. Sesay M, Chimzizi R, Chotpitayasunondh T, Crowley S, Duncombe C, et al. (2006) Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents, and adults in resource-limited settings. Geneva, Switzerland: WHO. Available: http://www.who.int/hiv/pub/guidelines/ctx/en/. Accessed 2013 Nov 30.
5. Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, et al. (2009) Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 53: 4789-4793.
6. Ong W, Sievers A, Leslie DE (2010) Mycobacterium tuberculosis and sulfamethoxazole susceptibility. Antimicrob Agents Chemother 54: 2748; author reply 2748-2749.
7. Huang TS, Kunin CM, Yan BS, Chen YS, Lee SS, et al. (2012) Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J Antimicrob Chemother 67: 633-637.
8. Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, et al. (2010) Daily cotrimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 375: 1278-1286.
9. Anglaret X, Chene G, Attia A, Toure S, Lafont S, et al. (1999) Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 353: 1463-1468. (Pubitemid 29204363)
10. Hanrahan CF, Golub JE, Mohapi L, Tshabangu N, Modisenyane T, et al. (2010) Body mass index and risk of tuberculosis and death. AIDS 24: 1501-1508.
11. Omar T, Schwartz S, Hanrahan C, Modisenyane T, Tshabangu N, et al. (2011) Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. AIDS 25: 87-94.
12. Rubin D (1987) Multiple Imputation for Non-Response in Surveys. New York: Wiley.
13. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, et al. (2004) Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364: 1428-1434. (Pubitemid 39370718)
14. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, et al. (1999) Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 353: 1469-1475. (Pubitemid 29204364)
15. Badri M, Ehrlich R, Wood R, Maartens G (2001) Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 15: 1143-1148. (Pubitemid 32549865)
16. Zachariah R, Spielmann MP, Chinji C, Gomani P, Arendt V, et al. (2003) Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 17: 1053-1061. (Pubitemid 36549718)
17. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, et al. (2008) Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 337: a257.
18. Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, et al. (2007) Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. JAcquirImmuneDeficSyndr 46: 56-61. (Pubitemid 47507434)
19. Dubar V, Lopez I, Gosset P, Aerts C, Voisin C, et al. (1990) The penetration of co-trimoxazole into alveolar macrophages and its effect on inflammatory and immunoregulatory functions. J Antimicrob Chemother 26: 791-802.